Clinical trials
Alagille Syndrome clinical trials
Below are recruiting alagille syndrome clinical trials, each written for real people, not researchers. We’re tracking 8 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07585097Recruiting
Long-term Safety Study of Odevixibat for Alagille Syndrome
This study follows patients with Alagille syndrome who are taking odevixibat to see how safe the medicine is over time. Alagille syndrome is a rare liver disease that affects bile flow, and odevixibat is a treatment that may help reduce itching and improve liver function.
BronAges 6 months+ - NCT06850038Recruiting
Long-term study of odevixibat in Alagille syndrome
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
Los Angeles, CaliforniaAges Any age - NCT07293897Recruiting
Study of Livmarli for Alagille Syndrome and PFIC
This study looks at how well Livmarli works for people with Alagille syndrome or a liver disease called PFIC. It uses data from prescriptions to understand the treatment's effects.
Tokyo, TokyoAges Any age - NCT07290257RecruitingPhase 4
Long-term safety study of Livmarli for Alagille syndrome or PFIC
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
BrusselsAges 2 months+ - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT07335523Recruiting
Testing for poor digestion in Alagille syndrome after liver transplant
This study looks for signs of poor digestion after a liver transplant in people with Alagille syndrome. You collect stool samples for 3 days while on a high-fat diet to see if your pancreas is making enough enzymes.
Aurora, ColoradoAges 7–50 - NCT06193928Recruiting
Long-term safety study of Livmarli in ALGS or PFIC
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
Los Angeles, CaliforniaAges Any age - NCT07411716Recruiting
Children's liver disease registry in Canada
This study creates a registry to track children with specific genetic liver conditions that cause cholestasis (slow bile flow). Being in the registry helps researchers better understand these diseases and may help future patients.
Calgary, AlbertaAges Up to 18 years
Hear when a new Alagille Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alagille syndrome?
- Yes. Clin2 currently lists 8 recruiting alagille syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alagille syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alagille syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.